



(51) International Patent Classification:

C12N 7/00 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/EP2017/072366

(22) International Filing Date:

06 September 2017 (06.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1616365.1 27 September 2016 (27.09.2016) GB

(71) Applicant: **HELSINGIN YLIOPISTO** [FI/FI]; Fabianinkatu 33, FI-00014 Helsingin Yliopisto, Helsinki (FI).(72) Inventors: **CERULLO, Vincenzo**; Uimarinpohku 10 C 15, FI-00330 Helsinki (FI). **CAPASSO, Cristian**; Vuolukiventie 1B b41, FI-00710 Helsinki (FI). **YLOSMÄKI, Erkki**; Teeritie 5, FI-01150 Sipoo (FI).(74) Agent: **SYMBIOSIS IP LIMITED**; Basepoint Business Centre, Vale Business Park, Crab Apple Way, Evesham Worcestershire WR111GP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NON-GENETIC MODIFICATION OF ENVELOPED VIRUSES




Figure 11

(57) Abstract: The invention concerns a modified enveloped virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; a pharmaceutical composition comprising same; and a method of treating cancer using same.



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

Non-genetic modification of enveloped viruses

Field of the Invention

The invention concerns a modified enveloped virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; a pharmaceutical composition comprising same; and a method of treating cancer using same.

Background of the Invention

The current paradigm for effective cancer therapeutics is the enhancement of the activity and increase in the amount of tumor infiltrating tumor-specific T-effector cells. These T-effector cells, named CD8⁺ T cells, specifically cytotoxic T cell lymphocytes (CTLs) are a critical component of the protective immune response against tumors. These tumor-specific CTLs can be found in tumor tissue and there is a clear correlation between the amount of tumor-infiltrated CTLs and patient survival.

A recent approval of antibodies targeting immune checkpoint molecules such as PD-1, PD-L1 and CTLA-4, which function to interrupt the negative feedback systems within the tumor microenvironment to enhance pre-existing anti-tumor immune responses, have been met with tremendous clinical excitement. The use of these immune checkpoint inhibitor antibodies can create durable responses in 10-20% of cancer patients. However, the remaining 80-90% of patients are not responding due to the lack of anti-tumor immune responses or other immune suppressive aspects of the tumor microenvironment. To broaden the patient population responding to checkpoint inhibitor- therapy we have developed an enveloped viral vector platform called PeptiENV for augmenting or generating a broad anti-tumor immunity and to recruit tumor-specific T-effector cells into the tumor microenvironment.

Advantageously, by treating patients with a combination of immunostimulatory PeptiENV viruses and immune checkpoint inhibitor antibodies we expect to increase the amount of responders to the immune checkpoint inhibitor therapies.

This patent application describes a PeptiENV platform, which includes a novel method for coating and inserting immunomodulatory peptides onto a viral envelope which can then be readily cross-presented on antigen presenting cells. Currently there are no methods for non-

genetically attaching peptides onto the viral envelope with a view to activating the immune system. WO2005/060541 teaches anti-viral peptides that are inserted into a viral coat for the purposes of disrupting the viral membrane and destroying same.

- 5 Some viruses have viral envelopes covering their protective protein capsids. The envelopes are typically derived from portions of the host cell membranes (phospholipids and proteins), but include some viral glycoproteins. They may help viruses avoid the host immune system. Glycoproteins on the surface of the envelope serve to identify and bind to receptor sites on the host's membrane. The viral envelope then fuses with the host's membrane, allowing the
- 10 capsid and viral genome to enter and infect the host. In addition to entering the host cell via fusion of the viral and host cell membranes, some viruses can alternatively use endocytosis as an entry mechanism.

Essentially, we have found a novel way of boosting anti-tumor immunity at the expense of

15 anti-viral immunity using known therapeutic and clinically approved viruses.

Statements of the Invention

According to a first aspect, there is provided a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2),

20 Vaccinia Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope.

Reference here in to a modified enveloped virus, is to a virus that is modified non-genetically

25 to include said at least one anti-tumor, tumor-specific peptide in its viral envelope. For the avoidance of doubt said virus may or may not include any other genetic modification(s) that make(s) it suitable for its purpose but the attachment of said at least one anti-tumor, tumor-specific peptide to or through the viral envelope is undertaken non-genetically.

30 Those skilled in the art will realise that some viruses have viral envelopes covering their protective protein capsids. The envelopes are typically derived from portions of the host cell membranes (phospholipids and proteins), but include some viral glycoproteins. They may help viruses avoid the host immune system. Glycoproteins on the surface of the envelope serve to identify and bind to receptor sites on the host's membrane. During infection, the

35 viral envelope fuses with the host's membrane, allowing the capsid and viral genome to

enter and infect the host. Peptides attached to or inserted in or taken through the viral envelope can thus be used as antigens to trigger an immune response.

5

Reference herein to an anti-tumor peptide is to a peptide that can elicit an immune response against a tumor.

10

Reference herein to a tumor-specific peptide is to a peptide that can elicit an immune response against a particular one or more tumour(s).

In a preferred embodiment said peptide is patient-identified or patient-specific.

15

As will be apparent to those skilled in the art the exact nature of the peptide can vary having regard to the nature of the tumour to be treated, indeed the specificity of the technology means that different anti-tumor, tumor-specific peptides will be used to treat individuals presenting with different types of cancer and even different anti-tumor, tumor-specific peptides can be used to treat individuals presenting with the same type of cancer.

20

In yet a further embodiment of the invention said peptide is between 8-50 amino acids long, ideally 15-35 amino acids long. Most ideally said peptide has a length selected from the group comprising: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50 amino acids.

25

Most ideally a plurality of said peptides are attached to or inserted in/through the viral envelope. These peptides may be identical or represent the same antigen with only a minor modification i.e. greater than 90% sequence identity with each other and most ideally greater than 92%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with each other.

30

Alternatively, a number of different anti-tumor, tumor-specific peptides are non-genetically attached to or inserted in/through the viral envelope.

35

More preferably, said peptide also comprises at least one cleavage site, such as, without limitation, a cathepsin cleavage site or a furin cleavage site. More preferably still, said peptide comprises at least one immunoproteasome processing site. Examples of these sites and their relative positioning with respect to the structure of the conjugated peptide are

shown in Figure 7. Ideally the one anti-tumor, tumor-specific peptide is positioned between a pair of immunoproteasome processing sites and upstream thereof is at least one cleavage site, ideally a furin cleavage site followed (upstream) by a cathepsin cleavage site.

- 5 Advantageously, we have found that these peptides when attached to or inserted in/through selected enveloped viruses (HSV-1 and -2, Vaccinia, VSV, MeV, Maraba virus and NDV) can trigger increased tumor-specific immune responses and drastically enhance anti-tumor efficacy by converting the anti-viral immunity into an anti-tumor immunity.
- 10 The elegance of this platform, compared to others, is that by attaching or inserting the patient-identified anti-tumor inducing tumor-specific peptides non-genetically to/in/through the viral envelope we can make clinical use of a medically approved virus. This means one can react very quickly to changes in a patients' tumor antigens that are presented on MHC-I simply by coating the virus with a new set of tumor-specific peptides derived from said
- 15 patient.

Another important feature of the invention is that the virus chosen for this platform needs to go through rigorous quality control and approval stages only once, thus saving time and money when compared to other platforms where viruses, having genetically introduced

20 modifications, need to go through checking stages every time a new modification or a peptide is introduced, thus making it virtually impossible to use these platforms in personalized medicine.

In a further preferred embodiment of the invention said peptide(s) is/are attached to or

25 inserted in/through said viral envelope using either a cell penetrating peptide or a cholesterol-conjugated peptide (purchased from PepScan or Ontores).

As is known to those skilled in the art, cell penetrating peptides (CPPs) are short peptides that facilitate cellular intake/uptake of various molecular equipment (from nanosize particles

30 to small chemical molecules and large fragments of DNA). This "cargo" is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions. The function of the CPP is to deliver the cargo into cells, a process that commonly occurs through endocytosis.

35 CPPs typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences

that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively. A third class of CPPs are the hydrophobic peptides, containing only apolar residues, with low net charge or have hydrophobic amino acid groups that are crucial for cellular uptake.

The invention envisages the use of any known CCP when linked with said anti-tumor, tumor-specific peptide.

Without wishing to be bound by an explanation of the mechanism of action, we consider that although CPPs normally deliver their cargo through the lipid bilayer, a peptide consisting of a CPP sequence together with our immunogenic peptide, partially passes through the lipid bilayer while part of it appears to stick, possibly via physical hydrophobic/-philic interactions, on the membrane sufficiently, if not exclusively, for our purposes.

An example of a CPP when conjugated to said peptide is shown in Figure 7B.

As is also known to those skilled in the art, cholesterol-conjugated peptides are short peptides attached to cholesterol. We have discovered that they can enter the viral envelope and so anchor the conjugated peptide within the viral coat. These peptides can be N- or C-terminally cholesterol conjugated.

Again, without wishing to be bound by an explanation of the mechanism of action, we consider that since cholesterol is a component of a lipid membrane, cholesterol-conjugated peptides find their "normal" location in the membrane. In fact we speculate that the hydroxy group on cholesterol interacts with the polar head groups of the membrane phospholipids and sphingolipids, while the bulky steroid and the hydrocarbon chain are embedded in the membrane, alongside the nonpolar fatty-acid chain of the other lipids.

An example of a cholesterol-conjugated peptide is shown in Figure 7A.

In a preferred embodiment of the invention the peptide for attaching to or inserting in/through said envelope comprises:

GRKKRRQRRRPQ (SEQ ID NO: 1) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

RQIKIWFQNRRMKWKK (SEQ ID NO: 2) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

KLALKLALKALKAAALKLA (SEQ ID NO: 3) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

5 RRRRRRRRRR (SEQ ID NO: 4) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

KETWWETWWTEWSQPKKKRKV (SEQ ID NO: 5) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

10 AGYLLGKINLKALAALAKKIL (SEQ ID NO: 6) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

AGLWRALWRLLRSLWRLLWRA (SEQ ID NO: 7) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide; or
a cholesterol moiety N- or C-terminus of the said anti-tumor, tumor-specific peptide.

15 In yet a further preferred embodiment of the invention the peptide for attaching to or inserting in/through said envelope comprises one of the following wherein the sequence SIINFEKL is simply representative of a MHC-I restricted epitope or peptide:

CPP peptides:

20 GRKKRRQRRRPQRRVRRALISLEQLESSIINFEKLTEW (SEQ ID NO: 8)

25 RQIKIWFQNRRMKWKKRWEKISIINFEKLYKLYK (SEQ ID NO: 9)

KLALKLALKALKAAALKLARWEKISIINFEKLYKLYK (SEQ ID NO: 10)

30 RRRRRRRRRRRWEKISIINFEKLYKLYK (SEQ ID NO: 11)

RWEKISIINFEKLYKLRRRRRRRRRR (SEQ ID NO: 12)

RWEKISIINFEKLYKLKETWWETWWTEWSQPKKKRKV (SEQ ID NO: 13)

35 RWEKISIINFEKLYKLAGYLLGKINLKALAALAKKIL (SEQ ID NO: 14)

AGLWRALWRLLRSLWRLLWRA RWEKISIINFEKLYKLYK (SEQ ID NO: 15)

GRKKRRQRRRPQRWEKISIINFEKLYKL (SEQ ID NO: 16)

40 GRKKRRQRRRPQRWEKISIINFEKL (SEQ ID NO: 17)

GRKKRRQRRRPQRWEKISIINFEKLYKLRWEKISIINFEKL (SEQ ID NO: 18) (where RWEKI and YKLWEKI are immunoproteasome processing sites).

Cholesterol-conjugated peptides:

5 LEQLESIIFEKLTEWRVRRALISC-cholesterol (SEQ ID NO: 19)

cholesterol-CRVRRALISLEQLESIIFEKLTEW (SEQ ID NO: 20)

10 cholesterol-CSIIFEKL (SEQ ID NO: 21)

cholesterol-CRWEKISIIFEKL (SEQ ID NO: 22) or

cholesterol-CRWEKISVYDFFVWLYKLRWEKISIIFEKL (SEQ ID NO: 23)

15 Accordingly, most preferably said anti-tumor, tumor-specific peptide(s) is/are attached to or inserted in/through said viral envelope using either a cell penetrating peptide or a cholesterol-conjugated peptide.

Typically virus particles were complexed with said CPP-peptide or Cholesterol-conjugated peptide by incubating same for approximately 15 min at 37 °C.

20

In yet another preferred embodiment said modified enveloped virus is provided with at least one anti-tumor, tumor-specific peptide that is MHC-I specific and so elicits an immune response ideally via MHC-I presentation on antigen presenting cells (APCs) for the activation of T-effector cells, named CD8⁺ T cells, specifically cytotoxic T cell lymphocytes (CTLs).

25

Additionally or alternatively, said modified enveloped virus is provided with at least one anti-tumor, tumor-specific peptide that is MHC-II specific and so elicits an immune response ideally via MHC-II presentation on antigen presenting cells (APCs) for the activation of a CD4⁺ (T-helper) cell response.

30

Accordingly, this invention also enables the use of different MHC-II epitopes coated onto the viral envelope to boost, alone or in combination with MHC-I epitopes, the immune response of the individual.

35 Additionally or alternatively the invention also enables the use of a peptide that (s) comprise(s) a fusion molecule including a plurality of different antigens.

Yet more preferably, there is provided a combination of different of said modified enveloped viruses where said viruses are selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus. Thus the invention concerns the use of at least two of any of the afore viruses and also extends to the use of a combination of any 3, 4, 5, 6 or 7 of the afore viruses.

Accordingly, the invention concerns the use of two different virus types or viral backbones enabling the Prime-Boost immunovirotherapy method where the treatment with a Prime (priming) virus of a particular species/genus coated with said peptides is followed by a treatment with Boost (boosting) virus of another particular species/genus (an immunologically distinct virus) coated with the same said peptides. The Prime-Boost immunovirotherapy method can dramatically further increase the tumor-specific T-cell immune responses by directing the majority of the immune responses created by the Prime-Boost method towards the said peptides.

When working the invention an enveloped virus modified as herein described may be used in the Prime-Boost immunovirotherapy in combination with another enveloped virus modified as herein described but presenting the same peptides or any other virus, such as an adenovirus, that has also been modified, including genetically or non-genetically, to present the same peptides.

Those skilled in the art will appreciate that since an enveloped virus, namely Herpes Simplex Virus 1 (HSV-1) is the most studied oncolytic enveloped virus and an engineered form of HSV-1 called T-VEC (Imlygic) is the first oncolytic virus showing efficacy in Phase III clinical trials and is the first oncolytic virus approved by both FDA and EMEA for the treatment of inoperable melanoma, it is critically important to introduce novel ways of boosting the anti-tumor immunity at the expense of the anti-viral immunity of these therapeutic and clinically approved viruses.

According to a second aspect of the invention there is therefore provided a pharmaceutical composition comprising:

1) a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein

said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; and

2) a suitable carrier.

- 5 According to a third aspect of the invention there is therefore provided a method for treating a cancer comprising exposing an individual to a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope.

More preferably still, said method involves, after a selected period, exposing said individual to another modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope and further wherein said virus is different from the one used for the prior exposure. Alternatively, in the Prime-Boost immunovirotherapy said method involves, after a selected period, exposing said individual to any another virus, such as an adenovirus, that has also been modified, including genetically or non-genetically, to present the same peptides. Alternatively, yet again, said method may be practiced by first using any virus that has been modified in any way, including genetically or non-genetically, to express selected peptides, followed by using the modified virus of the invention, having the same peptides, to provide the booster therapy.

25

In this way Prime-Boost immunovirotherapy can be practiced.

Ideally, said step of exposing an individual to a virus includes intratumoral, intranodal, intraperitoneal or intravenous injection.

30

Most preferably the cancer referred to herein includes any one or more of the following cancers: nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison

35

syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's
5 disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer,
10 penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer,
15 peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.

In a further embodiment of the invention, either after exposing an individual to a modified virus that expresses at least one anti-tumor, tumor-specific peptide or after exposing said
20 individual to an enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has the same or a majority of the same of said peptide(s) non-genetically attached to or inserted in/through the viral envelope, exposing said individual to a checkpoint inhibitor.
25 The check point inhibitor inhibits immune checkpoint molecules such as PD-1, PD-L1 and CTLA-4,

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word
30 "comprises", or variations such as "comprises" or "comprising" is used in an inclusive sense i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

All references, including any patent or patent application, cited in this specification are
35 hereby incorporated by reference. No admission is made that any reference constitutes prior

art. Further, no admission is made that any of the prior art constitutes part of the common general knowledge in the art.

Preferred features of each aspect of the invention may be as described in connection with any of the other aspects.

Other features of the present invention will become apparent from the following examples. Generally speaking, the invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including the accompanying claims and drawings).

Thus, features, integers, characteristics, compounds or chemical moieties described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith.

Moreover, unless stated otherwise, any feature disclosed herein may be replaced by an alternative feature serving the same or a similar purpose.

Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

An embodiment of the present invention will now be described by way of example only with reference to the following wherein:

Figure 1 is a summary of the data we have obtained when the anti-tumor, tumor-specific peptide is attached to different viral envelopes using either a CPP or a cholesterol-conjugated peptide;

Figure 2 shows CPP-containing peptides can be attached to the envelope of Herpes Simplex Virus 1. CPP containing and FITC-labelled peptide was complexed with HSV-1 and a sandwich ELISA was used for detection of the complexes. An anti-HSV-1 antibody was coated to the bottom of 96-well plate and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was used for the detection of the PeptiENV complex. Figure 2 lower panel shows CPP-containing peptides

have reduced diffusion time when complexed with HSV-1. Fluorescence correlation spectroscopy was used to analyze the diffusion kinetics of peptides complexed with HSV-1.

Figure 3 upper panel shows cholesterol-containing peptides can be attached to the envelope of Vaccinia virus. Cholesterol-containing and FITC-labelled peptides were complexed with Vaccinia virus. After the purification of the PeptiENV complexes by 36% sucrose cushion and ultracentrifugation, the purified complexes were analyzed by flow cytometry. A. Vaccinia virus without complexed peptides and B. Vaccinia virus complexed with cholesterol containing FITC-labelled peptides. Figure 3 middle panel shows cholesterol-containing peptides can be attached to the envelope of Vaccinia virus. Cholesterol-containing and FITC-labelled peptides were complexed with Vaccinia virus and a sandwich ELISA was used for the detection of the complexes. An anti-Vaccinia virus antibody was coated to the bottom of 96-well plate and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was used for the detection of the PeptiENV complexes. Figure 3 lower panel shows cholesterol-containing SIINFEKL-peptides are readily presented by dendritic cells. Mouse splenocytes were pulsed with cholesterol-containing SIINFEKL-peptides and the presentation of MHC I epitope SIINFEKL by CD11c positive DC-population was determined by flow cytometry.

Figure 4 upper panel shows CPP-containing peptides can be attached to the envelope of Vaccinia virus. CPP-containing and FITC-labelled peptides were complexed with Vaccinia virus. After the purification of the PeptiENV complexes by 36% sucrose cushion and ultracentrifugation, the purified complexes were analyzed by flow cytometry. A. HSV-1 without complexed peptides and B. HSV-1 complexed with CPP-containing FITC-labelled peptides. Figure 4 middle panel shows CPP-containing peptides can be attached to the envelope Vaccinia virus. CPP-containing and FITC-labelled peptide was complexed with Vaccinia virus and a sandwich ELISA was used for the detection of the complexes. An anti-Vaccinia virus antibody was coated to the bottom of 96-well plate and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was used for the detection of the PeptiENV complex. Figure 4 lower panel shows CPP-containing SIINFEKL-peptides are readily presented by dendritic cells. Mouse splenocytes were pulsed with CPP-containing SIINFEKL-peptides and the presentation of MHC I epitope SIINFEKL by CD11c positive DC-population was determined by flow cytometry.

Figure 5 upper panel shows PeptiENV can induce DC activation even with very low virus amount. Vaccinia virus was complexed with CPP- or cholesterol-containing SIINFEKL-

peptides and used for infection of mouse splenocytes. Two hours post-infection dendritic cells were analyzed by flow cytometry for the expression of DC activation markers. Figure 5 lower panel shows PeptiENV can induce the presentation of specific anti-tumor MHC class I epitopes by the CD11c-positive DCs even with very low virus amount. Vaccinia virus was
 5 complexed with CPP- or cholesterol-containing SIINFEKL-peptides and used for infection of mouse splenocytes. After two hours the presentation of MHC I epitope SIINFEKL by CD11c positive DC-population was determined by flow cytometry.

Figure 6 shows PeptiENV virus-peptide complexation has no effect on viral infectivity. Infectivity of PeptiENV was compared with normal non-complexed virus and cell viability was
 10 measured 3 days post-infection.

Figure 7 shows a schematic presentation of A) a cholesterol-conjugated immunomodulatory peptide and B) an immunomodulatory peptide having N-terminal cell penetrating peptide
 15 sequence. Color code for different functional sequences of the entities: In dark gray: cholesterol (A.) or cell penetrating sequence (B.). In red: cathepsin D/E cleavage site. In blue: furin cleavage site. In green: immunoproteasome processing sites. In black: the MHC-I restricted epitope.

Figure 8 shows that a variety of different CPP-sequences can be used to attach the anti-tumor peptides into the viral envelope. CPP-containing and FITC-labelled peptides were
 20 complexed with Vaccinia virus and a sandwich ELISA was used for the detection of the complexes. An anti-Vaccinia virus antibody was coated to the bottom of 96-well plate and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was used for the detection of the PeptiENV complexes.
 25

Figure 9 shows CPP-containing peptides do not have any antiviral effects and can be safely attached to the viral envelope without loss of infectivity or oncolytic effect. Four different cell
 30 lines, A549, MDMBA436, B16F10 and B16-OVA, were tested for viral infectivity and PeptiENV was compared to non-modified virus.

Figure 10 shows anti-tumour peptides anchored into viral envelope by CPP- or Cholesterol moieties induce extensive anti-tumor immunity leading to enhanced control of tumor growth and longer survival. A. Comparison of tumor growth between groups of Mock (treated with
 35 injection media only), Vaccinia virus only, PeptiENV with anti-tumor peptides attached to the viral envelope with a cholesterol moiety (PeptiENV VACV/chol) and PeptiENV with anti-

tumor peptides attached to the viral envelope with a CPP moiety (PeptiENV VACV/cpp). B. Kaplan-Meier survival curve of groups of mice treated with PeptiENV VACV/cpp, Vaccinia virus only, anti-tumor peptide alone (without virus) or Mock. C. Flow cytometric analysis of tumor-specific T-cells in treated tumor. PeptiENV can induce extensive filtration of tumor-specific effector T-cells in to the tumor microenvironment. D. Flow cytometric analysis of virus-specific T-cells in the tumor microenvironment. PeptiENV induces anti-viral immunity comparable to non-modified Vaccinia virus, while specifically inducing extensive anti-tumor immunity not presented by the non-modified Vaccinia virus.

Figure 11 shows PeptiENV VACV/chol and PeptiENV VACV/cpp treated mice elicit strong anti-tumor immune response and are protected from tumor rechallenge while Mock-treated mice are not protected. 500 000 B16-OVA cells were injected into the opposite flank of the previous tumor implantation and mice were followed for 14 days. No tumor growth was observed in mice treated with PeptiENV while the tumor incidence was 100% in the Mock treated group.

Figure 12 shows anti-tumor peptides anchored into Herpes simplex virus 1 (HSV-1) envelope by CPP moiety induce strong anti-tumor immunity leading to enhanced control of tumor growth. A. Tumor growth curve of PeptiENV HSV-1/cpp, HSV-1 only and Mock treated groups. B. Flow cytometric analysis of tumor-specific T-cells in treated tumor. PeptiENV can induce extensive filtration of tumor-specific effector T-cells in to the tumor microenvironment.

Figure 13 shows surface plasmon resonance (SPR) measurements to confirm the high affinity of CPP-containing anti-tumor peptides to the viral envelope. Two-site binding kinetic fit model was used for the analysis of the SPR data.

Specific description

Materials and methods:

Peptides:

Peptides used in this study are listed below and were all purchased from PepScan:

CPP peptides:

GRKKRRQRRRPQRVRRALISLEQLESIIINFEKLTEW (SEQ ID NO: 8)

GRKKRRQRRRPQRVRRALISLEQLESIIINFEKLTEW-FITC (SEQ ID NO: 24)

RQIKIWFQNRRMKWKKRWEKISIINFEEKLYKLK-FITC (SEQ ID NO: 25)

KLALKLALKALKAAKLARWEKISIINFEEKLYKLK-FITC (SEQ ID NO: 26)

RRRRRRRRRRRWEKISIINFEEKLYKLK-FITC (SEQ ID NO: 27)

FITC -RWEKISIINFEEKLYKLRRRRRRRRRR (SEQ ID NO: 28)

FITC-RWEKISIINFEEKLYKLKETWWETWWTEWSQPKKKRKV (SEQ ID NO: 29)

FITC-RWEKISIINFEEKLYKLAGYLLGKINLKALAALAKKIL (SEQ ID NO: 30)

GLWRALWRLRLSLWRLLWRARWEKISIINFEEKLYKLK-FITC (SEQ ID NO: 31)

GRKKRRQRRRPQRWEKISIINFEEKL (SEQ ID NO: 17)

GRKKRRQRRRPQRWEKISIINFEEKLYKLWEKISIINFEEKL (SEQ ID NO: 18)

Cholesterol-conjugated peptides:

LEQLESIINFEEKLTEWRVRRALISC-cholesterol (SEQ ID NO: 19)

FITC-LEQLESIINFEEKLTEWRVRRALISC-cholesterol (SEQ ID NO: 32)

cholesterol-CRVRRALISLEQLESIINFEEKLTEW (SEQ ID NO: 20)

cholesterol-CRVRRALISLEQLESIINFEEKLTEW-FITC (SEQ ID NO: 33)

cholesterol-CSIINFEEKL (SEQ ID NO: 21)

cholesterol-CRWEKISIINFEEKL (SEQ ID NO: 22)

cholesterol-CRWEKISVYDFFVWLYKLWEKISIINFEEKL (SEQ ID NO: 23)

Cell lines

Human lung carcinoma cell line A549, African Green monkey kidney epithelial cell line Vero (B) and Murine melanoma cell lines B16/OVA and B16-F10 were cultured in DMEM with 10% foetal calf serum (FBS) (Life Technologies) 1% L-glutamine and 1% penicillin/streptomycin at 37 °C/ 5% CO₂. Human triple negative breast cancer cell line MDMBA436 was cultured in RPMI with 10% foetal calf serum (FBS) (Life Technologies) 1% L-glutamine and 1% penicillin/streptomycin at 37 °C/ 5% CO₂.

Production of viruses

Herpes simplex virus 1 was produced in Vero cells and purified with sucrose gradient ultracentrifugation and eluted in 20 mM MES, 100 mM NaCl, 30 mM Tris-HCl (pH 7.2).

Western reserve strain of Vaccinia virus (VVDD-mDAI-RFP) was produced in A549 cells and purified through 36% sucrose cushion ultracentrifugation and eluted in 1mM Tris (pH 9.0).

5

ELISAs

2,5x10⁷ Vaccinia virus particles were complexed with 8ug of either CPP-peptide-FITC or cholesterol-conjugated peptide-FITC in 100ul of DMEM for 15 min at 37 °C. After complexation, unbound peptides were removed by ultracentrifugation (20.000g, 40-80mins) through 36% sucrose cushion in 1mM Tris (pH 9.0). For ELISA, anti-Vaccinia polyclonal antibody (Abcam) was coated o/n at 4 °C into maxisorb 96-well immunoplates at the concentration of 2ug/ml. Vaccinia-peptide complexes were incubated for 30-60min at 37 °C or RT and washed with 1xPBS for three times. Complexes were detected with anti-FITC antibody conjugated to horseradish peroxidase (Abcam) (1:5000 dilution in 2%BSA-PBS).

10

2,5x10⁷ Herpes simplex 1 virus particles were complexed with 8ug of either CPP-peptide-FITC or cholesterol-conjugated peptide-FITC in 100ul of DMEM for 15 min at 37 °C. For ELISA, anti-HSV-1 polyclonal antibody (Abcam) was coated o/n at 4 °C into maxisorb 96-well immunoplates at the concentration of 2ug/ml. HSV-1-peptide complexes were incubated for 30-60min at 37 °C or RT and washed with 1xPBS for three times. Complexes were detected with anti-FITC antibody conjugated to horseradish peroxidase (Abcam) (1:5000 dilution in 2%BSA-PBS).

15

20

Flow cytometry

5x10⁷ Vaccinia virus particles were complexed with 24ug of either CPP-peptide-FITC or cholesterol-conjugated peptide-FITC in 200ul of DMEM for 15 min at 37 °C. After complexation, unbound peptides were removed by ultracentrifugation (20.000g, 40-80mins) through 36% sucrose cushion in 1mM Tris (pH 9.0) and eluted to 2%Formalin in PBS. After fixing, formalin was removed with another ultracentrifugation (20.000g, 40-80mins) through 36% sucrose cushion and pellet was eluted to 1x ultrapure PBS (Gibco). Flow cytometry was performed with Apogee A50 Micro Flow Cytometer (Apogee) and FITC detection was used for assessing the complexes.

25

30

Cross-presentation experiments

2x10⁶ spleenocytes in 800 µL of 10% RPMI-1640 culture media were incubated with 200 µL of GRKKRRQRRRPQRRRRLISLEQLESIIINFEKLTEW (SEQ ID NO: 8),

35

LEQLESIINFEKLTEWRVRRALISC-cholesterol (SEQ ID NO: 19) or cholesterol-CRVRRALISLEQLESIINFEKLTEW (SEQ ID NO: 20) peptide dilution (0.19 µg/µL).

The vaccinia-peptide complexes were prepared as described for ELISAs. After 2 h of incubation cells were washed and stained with either APC anti-mouse H-2Kb bound to SIINFEKL or APC Mouse IgG1, κ Isotype Ctrl (BioLegend, San Diego, CA, USA), and the samples were analyzed by flow cytometry.

Cell Viability Assay

Cell viability was measured using the CellTiterGlo 96 Aqueous One Solution Cell Proliferation Assay (Promega), and a multi-well plate reader (Varioscan; ThermoLabsystems) to determine the luminescence of the samples.

Surface plasmon resonance

Measurements were performed using a multi-parametric SPR Navi™ 220A instrument (Bionavis Ltd, Tampere, Finland). Phosphate buffered saline (PBS) (pH 7.4) was used as a running buffer. A constant flow rate of 20 µL/min was used throughout the experiments, and temperature was set to +20°C. Laser light with a wavelength of 670 nm was used for surface plasmon excitation.

A sensor slide with a silicon dioxide surface was activated by 5 min of plasma treatment followed by coating with APTES ((3-aminopropyl)triethoxysilane) by incubating the sensor in 50 mM APTES in isopropanol for 4 h. The sensor was then washed and placed into the SPR device, and viruses were immobilized *in situ* on the sensor surface of the two test channels by injecting 1.1×10^7 pfu of VACV in PBS (pH 7.4) for approximately 12 min, followed by a 3-min wash with PBS. CPP-containing anti-tumor peptide or peptide without CPP sequence (non-interacting control) was then injected into both flow channels of the flow cell in parallel, with increasing peptide concentrations ranging from 1.23 µM to 100 µM.

Animal experiments

C57BL/6JOlaHsd-mouse strain was used in all animal experiment. 350000 B16-OVA-cells were injected in the right flank of mice (in rechallence experiment, cells were injected in to the left flank) and when the tumor size reached approximately 50mm³ (10-12 days after injection) mice were treated with non-modified viruses, PeptiENV-platform, peptides only or injection media only (Mock). Mice were treated on day 0, 2 and then a booster treatment

was given on day 8-10. Tumors were measured every second day until the tumor size reached the maximum allowed.

Claims

1. A modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope.
2. The modified enveloped virus according to claim 1 wherein said peptide has a length selected from the group comprising: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50 amino acids.
3. The modified enveloped virus according to claim 1 or claim 2 wherein a plurality of said peptides are non-genetically attached to or inserted in/through the viral envelope.
4. The modified enveloped virus according to claim 3 wherein said peptides are identical; said peptides have greater than 90%, 91%, 92%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with each other; or said peptides are representative of a number of different antigens.
5. The modified enveloped virus according to any one of the preceding claims wherein said peptide(s) is/are MHC-I restricted.
6. The modified enveloped virus according to any one of the preceding claims wherein said peptide(s) is/are MHC-II restricted.
7. The modified enveloped virus according to any one of claims 3-6 wherein said peptides comprise a mix of MHC-I restricted peptides and MHC-II restricted peptides.
8. The modified enveloped virus according to any one of the preceding claims wherein said peptide(s) comprise(s) a fusion molecule including a plurality of different antigens.
9. The modified enveloped virus according to any one of claims 1-8 wherein said peptide also comprises at least one cleavage site.
10. The modified enveloped virus according to any one of claims 1-9 wherein said peptide also comprises at least one immunoproteasome processing site.
11. The modified enveloped virus according to any one of claims 1-10 wherein said peptide is positioned between a pair of immunoproteasome processing sites and upstream or downstream thereof is at least one cleavage site.
12. The modified enveloped virus according to any one of the preceding claims wherein said peptide(s) are non-covalently attached to or inserted in/through the viral envelope.

13. The modified enveloped virus according to any one of the preceding claims wherein said peptide(s) is/are non-genetically attached to or inserted in/through said viral envelope using either a cell penetrating peptide or a cholesterol-conjugated peptide.

14. The modified enveloped virus according to any one of the preceding claims wherein said peptide(s) is/are non-genetically attached to or inserted in/through said viral envelope using either a cell penetrating peptide or a cholesterol-conjugated peptide selected from the group comprising:

GRKKRRQRRRPQ (SEQ ID NO: 1), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

RQIKIWFQNRRMKWKK (SEQ ID NO: 2), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

KLALKLALKALKAAALKLA (SEQ ID NO: 3), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

RRRRRRRRR (SEQ ID NO: 4), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

KETWWETWWTEWSQPKKKRKV (SEQ ID NO: 5), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

AGYLLGKINLKALAALAKKIL (SEQ ID NO: 6), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;

AGLWRALWRLLRSLWRLWRA (SEQ ID NO: 7), CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide; and a cholesterol moiety N- or C-terminus of the said anti-tumor, tumor-specific peptide.

15. The modified enveloped virus according to claim 14 wherein said peptide(s) is/are selected from the group comprising:

GRKKRRQRRRPQRVRRALISLEQLESIINFEKLTEW (SEQ ID NO: 8);

RQIKIWFQNRRMKWKKRWEKISIINFEKLYKLYK (SEQ ID NO: 9);

KLALKLALKALKAAALKLARWEKISIINFEKLYKLYK (SEQ ID NO: 10);

RRRRRRRRRRRWEKISIINFEKLYKLYK (SEQ ID NO: 11);

RWEKISIINFEKLYKLRRRRRRRRR (SEQ ID NO: 12);

RWEKISIINFEKLYKLYKETWWETWWTEWSQPKKKRKV (SEQ ID NO: 13);

RWEKISIINFEKLYKLAGYLLGKINLKALAALAKKIL (SEQ ID NO: 14);

AGLWRALWRLLRSLWRLWRA RWEKISIINFEKLYKLYK (SEQ ID NO: 15);

GRKKRRQRRRPQRWEKISIINFEKLYKLYK (SEQ ID NO: 16);

GRKKRRQRRRPQRWEKISIINFEKL (SEQ ID NO: 17);

GRKKRRQRRRPQRWEKISIINFEKLYKL RWEKISIINFEKL (SEQ ID NO: 18);

LEQLESIINFEKLTEWRVRRALISC-cholesterol (SEQ ID NO: 19);

cholesterol-CRVRRALISLEQLESIIINFEKLTEW (SEQ ID NO: 20);
 cholesterol-CSIINFEKL (SEQ ID NO: 21);
 cholesterol-CRWEKISIINFEKL (SEQ ID NO: 22);
 cholesterol-CRWEKISVYDFFVWLYKLRWEKISIINFEKL (SEQ ID NO: 23);
 5 GRKKRRQRRRPQRRVRRALISLEQLESIIINFEKLTEW-FITC (SEQ ID NO: 24);
 RQIKIWFQNRRMKWKKRWEKISIINFEKLYKLK-FITC (SEQ ID NO: 25);
 10 KLALKLALKALKAAKLARWEKISIINFEKLYKLK-FITC (SEQ ID NO: 26);
 RRRRRRRRRRRWEKISIINFEKLYKLK-FITC (SEQ ID NO: 27);
 FITC -RWEKISIINFEKLYKLRRRRRRRRR (SEQ ID NO: 28);
 15 FITC-RWEKISIINFEKLYKLKETWWETWWTEWSQPKKKRKV (SEQ ID NO: 29);
 FITC-RWEKISIINFEKLYKLAGYLLGKINLKALAALAKKIL (SEQ ID NO: 30) and
 GLWRALWRLLRSLWRLLRARWEKISIINFEKLYKLK-FITC (SEQ ID NO: 31).

16. The modified enveloped virus according to any one of the preceding claims wherein there is provided a combination of different non-genetically modified enveloped viruses selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus.
17. The modified enveloped virus according to claim 16 wherein said combination comprises any 2, 3, 4, 5, 6 or 7 of the afore viruses modified to comprise at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope of said virus.
18. A pharmaceutical composition comprising: a modified enveloped virus according to any one of claims 1-17 and a suitable carrier.
19. A method for treating a cancer comprising exposing an individual to a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope.
20. The method according to claim 19 wherein said method involves, after a selected period, exposing said individual to another modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV),

Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope and further wherein said virus is different from the one used for the prior exposure.

- 5 21. The method according to claim 20 wherein said another modified enveloped virus is coated with the same or a majority of the same said peptides as the first modified enveloped virus.
22. The method according to any one of claims 19-21 wherein after exposure to said one or more virus(es) said individual is further exposed to a checkpoint inhibitor.
- 10 23. A method for treating a cancer comprising exposing an individual to a modified virus that expresses at least one anti-tumor, tumor-specific peptide and then, after a selected period, exposing said individual to an enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has the same or a majority of the same of said peptide(s) non-genetically attached to or inserted in/through the viral envelope.
- 15 24. The method according to claim 23 wherein either after exposing an individual to a modified virus that expresses at least one anti-tumor, tumor-specific peptide or after exposing said individual to an enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has the same or a majority of the same of said peptide(s) non-genetically attached to or inserted in/through the viral envelope, exposing said individual to a checkpoint inhibitor.
- 20 25. The modified enveloped virus according to claims 1-17, the pharmaceutical composition according to claim 18 and the method according to claims 19-24 as substantially herein described.

2/15




Figure 2




Figure 3

4/15




Figure 3
Continued





Figure 4

6/15




Figure 4
Continued

7/15





Figure 5




Figure 6

9/15

A
cholesterol-CRVRRALISLEQLESIINFEKLTEW (SEQ ID NO:20)

B
GRKKRRQRRRPQRVRRALISLEQLESIINFEKLTEW
(SEQ ID NO:8)

Figure 7

A wide variety of different cell penetrating peptide (CPP) sequences can be used to attach peptides to the viral envelope




Figure 8

A wide variety of different cell penetrating peptide (CPP) sequences
can be used to attach peptides to the viral envelope




Figure 8
Continued

Attaching peptides into the viral envelope does not decrease viral infectivity




Figure 9

Anti-tumour peptides anchored into viral envelope by CPP or Cholesterol moieties induces extensive anti-tumour immunity leading to enhanced tumour control and longer survival




Figure 10

14/15

Anti-tumour peptides anchored into viral envelope by CPP or Cholesterol moieties induces extensive anti-tumour immunity and protects treated mice from tumour rechallenge




Figure 11

Anti-tumour peptides anchored into viral envelope by CPP moiety induces extensive anti-tumour immunity leading to enhanced tumour control




Figure 12

CPP-containing anti-tumour peptides have
femtomolar affinity to viral envelope




Figure 13

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/072366

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N7/00 A61K39/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CRISTIAN CAPASSO ET AL: "Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma", ONCOIMMUNOLOGY, vol. 5, no. 4, 29 October 2015 (2015-10-29), page e1105429, XP055271942, DOI: 10.1080/2162402X.2015.1105429 the whole document figure 1 ----- -/--	1-12,18, 19,23,25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 2017

Date of mailing of the international search report

08/11/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Lewis, Birgit

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/072366

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SUSANNE HEIDER ET AL: "Biomedical applications of glycosylphosphatidylinositol-anchored proteins", JOURNAL OF LIPID RESEARCH, vol. 57, no. 10, 19 August 2016 (2016-08-19), pages 1778-1788, XP055419435, US ISSN: 0022-2275, DOI: 10.1194/jlr.R070201 abstract figures 1,2 page 1780 page 1785, left-hand column, last paragraph - right-hand column, paragraph 1 -----	1-12,18, 19,23,25
X	JAINA M. PATEL ET AL: "Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity : Protein transfer of tumor antigens onto VLPs", BIOTECHNOLOGY AND BIOENGINEERING, vol. 112, no. 6, 1 June 2015 (2015-06-01), pages 1102-1110, XP055419535, ISSN: 0006-3592, DOI: 10.1002/bit.25537 abstract page 1103, left-hand column, last paragraph page 1108, right-hand column, last paragraph - page 1109, right-hand column, paragraph 1 -----	1,3,4, 12,18, 19,25
A	WO 03/063770 A2 (CTL IMMUNOTHERAPIES CORP) 7 August 2003 (2003-08-07) paragraphs [0007], [0016], [0071]; claims 1-21 -----	9-11
A	METZNER CHRISTOPH ET AL: "Association of glycosylphosphatidylinositol-anchored protein with retroviral particles", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 22, no. 8, 1 August 2008 (2008-08-01), pages 2734-2739, XP002533866, ISSN: 0892-6638, DOI: 10.1096/FJ.08-108217 -----	1-25
A	WO 2015/177098 A2 (HELSINGIN YLIOPISTO) 26 November 2015 (2015-11-26) figure 1 the whole document ----- -/--	1-25

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/072366

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CRISTIAN CAPASSO ET AL: "Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors", BIOMEDICINES, vol. 1, no. 1, 4 December 2013 (2013-12-04), pages 3-16, XP055419606, DOI: 10.3390/biomedicines1010003 figure 1 -----	1-25
A	WO 2015/027163 A1 (UNIV PITTSBURGH) 26 February 2015 (2015-02-26) the whole document -----	1-25
A	HASAN REHMAN ET AL: "Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 4, no. 1, 20 September 2016 (2016-09-20), XP055419708, DOI: 10.1186/s40425-016-0158-5 the whole document -----	1-25
A	E. HASTIE ET AL: "Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer", JOURNAL OF GENERAL VIROLOGY, vol. 93, no. Pt_12, 10 October 2012 (2012-10-10), pages 2529-2545, XP055192133, ISSN: 0022-1317, DOI: 10.1099/vir.0.046672-0 the whole document -----	1-25
T	AMELIA AITKEN ET AL: "Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies", BIOMEDICINES, vol. 5, no. 1, 4 January 2017 (2017-01-04), page 3, XP055419683, DOI: 10.3390/biomedicines5010003 abstract table 1 -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/072366

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03063770	A2	07-08-2003	AT 494387 T 15-01-2011
		AU 2008229722 A1 30-10-2008	
		CA 2469738 A1 07-08-2003	
		CN 1612935 A 04-05-2005	
		CN 101024842 A 29-08-2007	
		DK 1453471 T3 28-03-2011	
		EP 1453471 A2 08-09-2004	
		EP 2314712 A1 27-04-2011	
		ES 2358642 T3 12-05-2011	
		HK 1068807 A1 07-10-2011	
		HK 1075473 A1 22-02-2008	
		MX PA04005382 A 24-02-2005	
		US 2003228634 A1 11-12-2003	
		US 2004132088 A1 08-07-2004	
		US 2004203051 A1 14-10-2004	
		WO 03063770 A2 07-08-2003	
WO 2015177098	A2	26-11-2015	AU 2015263286 A1 24-11-2016
		CA 2949174 A1 26-11-2015	
		CN 107073089 A 18-08-2017	
		EP 3145537 A2 29-03-2017	
		JP 2017522267 A 10-08-2017	
		KR 20170012326 A 02-02-2017	
		US 2017080069 A1 23-03-2017	
		WO 2015177098 A2 26-11-2015	
WO 2015027163	A1	26-02-2015	AU 2014308648 A1 03-03-2016
		CA 2921041 A1 26-02-2015	
		CN 105658795 A 08-06-2016	
		EA 201690444 A1 31-08-2016	
		EP 3036329 A1 29-06-2016	
		HK 1223402 A1 28-07-2017	
		JP 2016527920 A 15-09-2016	
		KR 20160044529 A 25-04-2016	
		MD 20160027 A2 31-08-2016	
		PE 06732016 A1 21-07-2016	
		PH 12016500329 A1 02-05-2016	
		SG 11201600960P A 30-03-2016	
		US 2016235793 A1 18-08-2016	
		WO 2015027163 A1 26-02-2015	